Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Files An 8-K Financial Statements and ExhibitsItem 9.01
Karyopharm Therapeutics Inc. ExhibitEX-99.1 2 d459715dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Targeting Disease at the Nuclear Pore Karyopharm Announces Successful Outcome from Phase 2 Portion of Phase 2/3 SEAL Study Evaluating Selinexor in Patients with Previously Treated Advanced Dedifferentiated Liposarcoma – The Primary Objective of Progression-Free Survival Favored Selinexor over Placebo; Hazard Ratio of 0.60 (RECIST v1.1),…To view the full exhibit click here
About Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases. The Company has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. It lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. Its product pipeline includes Verdinexor (KPT-335), an oral SINE compound; KPT-9274, a dual p21-activated kinase 4 (PAK4)/Nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, and KPT-350, a compound in development for the treatment of neurological disorders.
